Glenmark Pharmaceutical today announced that its US subsidiary Glenmark (Q,N,C,F)* Generics has received final approval from the USFDA for Atovaquone and Proguanil hydrochloride 250 mg/ 100 mg tablets, their generic version of GSK`s Malarone tablets.
GSK currently markets its product as Malarone in the United States indicated for the prevention and treatment of malaria. Total US sales as reported by IMS health for the 12 month period ending December 2009 were approximately USD 56 million.
In April 2010, the company confirmed the settlement of litigation pending between Glenmark and GSK over patents actions concerning Atovaquone and Proguanil hydrochloride 250 mg/ 100 mg tablets.
GSK currently markets its product as Malarone in the United States indicated for the prevention and treatment of malaria. Total US sales as reported by IMS health for the 12 month period ending December 2009 were approximately USD 56 million.
In April 2010, the company confirmed the settlement of litigation pending between Glenmark and GSK over patents actions concerning Atovaquone and Proguanil hydrochloride 250 mg/ 100 mg tablets.
No comments:
Post a Comment